Topical Calcineurin Inhibitors and Malignancy Risk.
Context: The approval of topical calcineurin inhibitors (TCIs) has been a significant breakthrough for the treatment of atopic dermatitis due tomuchlower systemic absorption and not causing skin atrophy even after long-term use that have made them become popular replacements for topical corticostero...
| Publicado en: | International Journal of Cancer Management Vol. 10; no. 4; pp. 1 - 7 |
|---|---|
| Autores principales: | , , , |
| Formato: | Journal Article |
| Publicado: |
Medical Journals Commission of the Ministry of Health & Medical Education
Apr2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |